Enzyme (MLN) Review: OG Score & Community Audit

Melon is one of the older defi projects melon has been around for years before before it rebranded to enzyme giving it real long term history instead of being a new idea, but long term price volatility has turned it into highly risky crypto token from $258 to $1.26 crash caused significant damage to early investors people who bought in hope for long term big profits almost lost total money.
Despite smaller market cap and huge price crashes token is still available on some mid tier exchanges even though large portion of community already left the project and token, the biggest hurdle it's facing is market trend and hype has changed towards Ai and meme coins, so alongside the price the trading volume also shrinked to few hundred thousand dollars.
Basically while this is a real older project with an actual product but like most tokens its price has caused problems for long term holders.

Enzyme has spent years building tools for onchain asset management instead of chasing short term trends, anyone can create a non custodial vault, but every vault follows the strategy chosen by its manager, that means two vaults on the same protocol can produce completely different results, even when they use the same infrastructure, the Enzyme documentation explains how vault permissions, fee structures, supported assets, and risk controls work.   That detail is easy to overlook, a strong protocol cannot protect users from poor investment decisions made by a vault manager, looking at the manager's track record is just as important as checking the protocol itself, that's one reason experienced users compare vault performance before depositing funds instead of focusing only on the MLN token price.

Enzyme Finance has been around since the early days of DeFi and remains one of the more established on-chain asset management protocols, but it isn't without risks. Liquidity isn't particularly deep, so larger trades can still have an outsized impact on the market. At the protocol level, vaults also depend on accurate oracle pricing and proper asset tracking, if rewards or airdropped assets aren't accounted for, vault values can become temporarily mispriced. Another thing to watch is that each vault ultimately depends on its manager. While the protocol itself is non-custodial and audited, fund managers still control key vault settings, so users are placing trust not just in Enzyme's code but also in whoever is running the vault.

It's a serious, OG DeFi protocol with a real team and institutional partnerships, but its tokenomics feel like a relic, and there's a troubling lack of lively community buzz. A competent, stale sleeping giant. A prominent red flag is its market visibility, after getting delisted from OKX in October 2025. In theory, the tech is great. But a dead community and terrible market presence for such an old project mean the upside is capped until they re-engage with actual humans. Here's the official link regarding the delisting of Enzyme (MLN) from OKX: https://www.okx.com/en-us/help/okx-to-delist-slerf-alpha-badger-oas-mln-and-aidoge-spot-trading-pairs

Enzyme provides on-chain asset management infrastructure but I can see wallet concentration and low adoption, with no confirmed insider dumping yet whale influence is a big risk due to thin liquidity in the token. See more about wallet concentration and dominance here plus this so very low liquidity: https://dexscreener.com/ethereum/0x15ab0333985FD1E289adF4fBBe19261454776642 For a token build to target fund management it's really not giving me that achievement so far and it's no where near beginner friendly.

The project is a high grade financial plumbing. However, the MLN token is a failing investment. If you care about security and tech, Enzyme is a gold standard. If you care about token performance, the OKX delisting and inflationary minting are terminal red flags. Because the protocol itself is so successful at securing $123M in assets without a hack, the technical praise wins, but only as a tool, not as a coin. https://www.rootdata.com/news/394690